[ad_1] GLPG3667 is an investigational, novel, oral, reversible, and selective tyrosine kinase 2 (TYK2) inhibitor GLPG3667 is currently in development for the treatment of inflammatory and auto-immune diseases and is…
Tag: Galapagos NV
Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis
[ad_1] Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis OLINGUITO Phase 3 program in adults with axial spondyloarthritis (AxSpA) to include two parallel studies to…